Evidence map›Paper›PMID 36498506›Full record

ArticleJournal of clinical medicine2022

Factors That Affect Survival Outcomes in Patients with Endometrial Clear Cell Carcinoma.

Vasilios Pergialiotis, Dimitrios Haidopoulos, Theano Christodoulou, Ioannis Rodolakis, Ioannis Prokopakis, Michalis Liontos, Alexandros Rodolakis, Nikolaos Thomakos

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Vasilios PergialiotisFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.ORCID 0000-0003-4510-1633
Dimitrios HaidopoulosFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Theano ChristodoulouFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Ioannis RodolakisFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Ioannis ProkopakisFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Michalis LiontosFirst Department of Propedeutic Surgery, National Kapodistrian University of Athens, Hippocration Hospital, 11528 Athens, Greece.ORCID 0000-0001-7192-4575
Alexandros RodolakisFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Nikolaos ThomakosFirst Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, "Alexandra" General Hospital, 11528 Athens, Greece.
Alexandra Hospital · GRNational and Kapodistrian University of Athens · GR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Clear cell carcinoma (CCC) is a rare aggressive histologic subtype of endometrial cancer with a high relapse rate. In the present study, we sought to evaluate the prognostic factors of disease relapse and overall survival. Methods: We conducted retrospective cohort studies that included endometrial CCC patients treated at our institution. Predictive variables of survival outcomes were evaluated considering factors that determine the survival of patients with endometrioid carcinoma. Results: Fifty-five patients with a median age of 68 years and a median follow-up period of 31 months were included in the present study. Recurrence-free and overall survival rates did not differ among patients with early-stage and advanced-stage disease (RFS HR 1.51 (95% CI 0.63, 3.61), OS HR 1.36 (0.56, 3.31)). Patients with upper abdominal metastases had significantly shorter progression-free and overall survival intervals (log-rank < 0.001). The Gehan-Breslow-Wilcoxon analysis indicated worse survival rates for patients with advanced disease (p = 0.040); however, the log-rank test that gave equal weight to all time points did not reveal significant differences (log-rank = 0.576). Conclusion: Clear cell carcinoma is an aggressive histologic subtype of endometrial cancer that seems to be moderately affected by known predictors of survival rates in endometrioid carcinoma patients, except for the disease stage. Further research is needed to evaluate whether the molecular profiling of these patients may help predict survival outcomes.

Indexed as

clear cell carcinomaendometrial cancerrecurrencesurvival

Identifiers

PMID36498506
PMCPMC9737404
OpenAlexW4309938330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.